TAVI Market Expected to Reach $16.94 Billion by 2030

According to a new report published by Allied Market Research, titled, “Transcatheter Aortic valve Implantation (TAVI) Market by Procedure Type: Global Opportunity Analysis and Industry Forecast, 2021–2030," the global TAVI market was valued at $4.56 billion in 2020, and is estimated to reach $16.94 billion by 2030, growing at a CAGR of 14.0% from 2021 to 2030.

Transcatheter aortic valve implantation (TAVI) is a minimally invasive heart procedure to replace thickened aortic valve. TAVI help to restore blood flow and reduce the signs and symptoms of aortic valve stenosis such as shortness of breath, fainting and fatigue and, chest pain. The factors that drive the growth of the global transcatheter aortic valve implantation market include increase in the prevalence of aortic stenosis, advancements in the transcatheter aortic valves and increase in adoption rate of TAVI valve.

The report segments the TAVI market based on approach or procedure used for the implantation. Major types of approaches are used to implant transcatheter aortic valve in the patients, which includes transfemoral procedure, subclavian procedure and others. Transfemoral implantation is stated as the standardized TAVI procedure, where in artificial valve is implanted through the femoral artery with minimal anaesthesia.  The wire is inserted in retrograde manner via aortic arch. The procedure has been accepted by majority of doctors due to the positive outcomes. However, this implantation has some complications due to greater distance of insertion from the aortic valve. The most well-known type of minimally invasive TF-TAVI procedure keeps on acquiring footing as an expanding number of doctors and surgeons keep on suggesting TAVI procedure due to its eminent clinical advantages.  

Europe accounted for a majority of the global transcatheter aortic valve implantation (TAVI) market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to the increase in prevalence of severe aortic stenosis cases and high adoption rate of advanced transcatheter aortic valves in this region. In addition, favorable reimbursement policies in certain European nations is the key to increase the adoption of TAVI procedures in this region.

The prevalence of symptomatic aortic stenosis is substantial in the UK and is expected to grow in future due to the growth in the number of high-risk aortic stenosis patients in the country. This number is expected to increase due to changes in lifestyles of the people, which include unhealthy dietary habits, lack of physical activity, and smoking. In addition, favorable reimbursement scenario of the UK further propels the TAVI market. Italy has a steady growing TAVR market due to high adoption rate of these procedures. Furthermore, Italy also offers an emerging market for several global players of TAVI as it has a large patient pool of aged population.

However, Asia-Pacific is expected to be the fastest growing region (in terms of value and volume) throughout the analysis period, owing to presence of ample growth opportunities in terms of unmet medical needs for the treatment of aortic stenosis.

Asia-Pacific is densely populated, with India and China being the most populated countries. The growth in older age population coupled with the rise in cases of aortic stenosis boosts the market. Furthermore, the increase in demand for transcatheter aortic valves, large number of healthcare reforms, and rise in focus of key players in launching technologically advanced transcatheter aortic valves further drives the TAVI market in the Asia-Pacific region. However, the unfavorable reimbursement scenario for TAVI, lack in advanced healthcare infrastructure, and high-cost of these specialized valves are expected to impede the growth of the TAVI market in these countries. The prevalence of symptomatic aortic stenosis in India has increased due to rise in population and changes in the lifestyle of people. Thus, the emerging markets have a huge potential for the market growth in valvular disease management area and is projected to provide lucrative growth opportunities for the manufacturers and distributors of transcatheter aortic valves owing to the aforementioned factors.

According to the estimates of the Japanese Cabinet Office published in the National Center for Biotechnology Information article, the life expectancy of the people in Japan is expected to increase to 90.3 years for females and 83.7 years for males by 2055. Hence, there is an increase in the aging population, which is prone to encounter aortic stenosis. Therefore, the Japanese government has taken several steps to accelerate the approval process for treatment devices and reduction of lag period for devices.

The key players profiled in this report include Abbott Laboratories, Blue Sail Medical, Boston Scientific Corporation, Bracco, Edward Life Sciences, JC Medical, JenaValve, Medtronic Plc., Meril Life Sciences, and Venus Medtech.

Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) is an infectious disease caused by the novel coronavirus (COVID-19), which originated in the Wuhan district in China in the late 2019. The virus was initially referred to as “novel coronavirus 2019” (2019-nCoV) by the WHO, However, on February 11, 2020, it was given the official name of SARS-CoV-2 by the International Committee on Taxonomy of Viruses. WHO declared COVID-19 as pandemic on March 11, 2020. The COVID-19 outbreak resulted in some changes in management of TAVI as huge number of hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. The non-essential procedures took a potential backlog due to rapidly rising COVID-19 cases. Delays in treatment are led to increase in number of patients waiting for the treatment, this creates pressure on healthcare resources and consideration of patients for aortic valve implantation.

Key Findings of the Study

• By procedure, the transfemoral and subclavian segment was the highest contributor to the TAVI market in 2020.
• Region wise, Europe garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.